T0	Outcomes 1919 1944	progression-free survival
T1	Outcomes 2010 2027	Efficacy analyses
T2	Outcomes 2079 2094	safety analyses
T3	Outcomes 2422 2457	3·1-9·0), progression-free survival
T4	Outcomes 2704 2749	grade 3 or 4 drug-related adverse events were
T5	Outcomes 2842 2861	methotrexate group)
T6	Outcomes 2885 2896	three [2%])
T7	Outcomes 2918 2929	vs 13 [8%])
T8	Outcomes 2951 2966	five [3%]), and
T9	Outcomes 2988 3016	vs 11 [7%]); serious adverse
T10	Outcomes 3177 3209	improvements in progression-free